Claims for Patent: 5,108,909

Summary for Patent: 5,108,909

Title:	Expression of TPA in mammalian cells
Abstract:	Improved expression of tPA in mammalian cells is achieved employing a promoter region functional in a mammalian cell with a DNA sequence coding for tPA, where the sequence is interrupted by at least one intron. Particularly, a viral promoter is employed in conjunction with a hybrid gene having portions of the coding sequence uninterrupted by introns as compared to the wild-type gene and coding sequences interrupted by introns or the wild-type gene or mutants thereof. Plasmid pSV7tPA2I was deposited on Feb. 14, 1985 and given A.T.C.C. Accession No. 40163.
Inventor(s):	Haigwood; Nancy L. (Oakland, CA)
Assignee:	Chiron Corporation (Emeryville, CA)
Application Number:	07/097,271
Patent Claims:	1. A DNA construct, comprising: a chimeric gene having a coding sequence for human tissue plasminogen activator with at least one intron of at least 100 bp at a site natural to the genomic form of human tissue plasminogen activator gene, wherein said intron includes a 5' splice site and a 3' splice site and provides increased expression of said chimeric gene relative to an uninterrupted coding sequence lacking all introns and wherein said chimeric gene is capable of producing mRNA having the proper reading frame wherein said gene contains fewer than the total number of introns present in the genomic form of the gene for human tissue plasminogen activator, and transcriptional initiation and termination regulatory sequences functional in a mammalian host, at least the initiation sequence being an initiation sequence other than the initiation sequence for the genomic form of the gene for human tissue plasminogen activator. 2. An expression vector capable of stable maintenance in a mammalian host comprising a DNA construct according to claim 1. 3. A mammalian cell in culture containing an expression vector according to claim 2. 4. A mammalian cell in culture wherein DNA construct according to claim 1 is integrated into a chromosome. 5. A DNA construct according to claim 1, wherein each of said introns is natural to human tissue plasminogen activator gene. 6. An expression vector capable of stable maintenance in a mammalian host comprising a DNA construct according to claim 5. 7. A DNA construct according to claim 5, wherein a 2.6 Kb EcoRI-EcoRI fragment from complete digestion with EcoRI of the genomic gene of human tissue plasminogen activator is substituted for an EcoRI-EcoRI region of a cDNA coding for human tissue plasminogen activator. 8. A mammalian cell in culture wherein a DNA construct according to claim 7 is integrated into a chromosome. 9. An expression vector capable of stable maintenance in a mammalian host comprising a DNA construct according to claim 7. 10. A mammalian cell in culture containing an expression vector according to claim 9. 11. A method for producing tissue plasminogen activator in a mammalian cell host comprising: providing a chimeric gene for human tissue plasminogen activator with at least one intron of at least 100 bp at a site natural to the genomic form of human tissue plasminogen activator gene, wherein said intron includes a 5' splice site and a 3' splice site and provides increased expression of said chimeric gene relative to an uninterrupted coding sequence lacking all introns and wherein said chimeric gene is capable of producing mRNA having the proper reading frame, wherein said gene contains fewer than the total number of introns present in the genomic form of the gene for human tissue plasminogen activator; placing said chimeric gene for human tissue plasminogen activator with at least one intron under the transcriptional control of a promoter region other than the promoter region natural to human tissue plasminogen activator gene; introducing said chimeric gene for human tissue plasminogen activator with at least one intron under control of said promoter region into said mammalian cell host; culturing said mammalian cell host; and expressing said chimeric gene for human tissue plasminogen activator with at lest one intron in said mammalian cell host. 12. A method according to claim 11, wherein said chimeric gene comprises cDNA and genomic DNA having at least one intron. 13. A DNA construct according to claim 12, wherein a 2.6 Kb EcoRI-EcoRI fragment from complete digestion with EcoRI of the genomic gene of human tissue plasminogen activator is substituted for an EcoRI-EcoRI region of a cDNA coding for human tissue plasminogen activator. 14. A method according to claim 4, wherein the introns are natural to human tissue plasminogen activator gene. 15. A method according claim 14, having a viral promoter region for regulating transcription of said gene.

Details for Patent 5,108,909

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2009-04-28
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2009-04-28
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2009-04-28